VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 560 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2015. The put-call ratio across all filers is 2.18 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $1,000 | – | 25 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | -100.0% | 25 | 0.0% | 0.00% | – |
| Q4 2017 | $1,000 | – | 25 | 0.0% | 0.00% | – |
| Q3 2017 | $0 | – | 25 | 0.0% | 0.00% | – |
| Q2 2017 | $0 | – | 25 | 0.0% | 0.00% | – |
| Q1 2017 | $0 | – | 25 | 0.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 25 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $1,000 | -50.0% | 25 | -77.9% | 0.00% | 0.0% |
| Q2 2016 | $2,000 | -33.3% | 113 | +352.0% | 0.00% | -50.0% |
| Q4 2015 | $3,000 | -82.4% | 25 | -73.4% | 0.00% | -80.0% |
| Q3 2015 | $17,000 | -46.9% | 94 | -35.6% | 0.01% | -44.4% |
| Q2 2015 | $32,000 | +33.3% | 146 | -14.6% | 0.02% | +20.0% |
| Q4 2014 | $24,000 | +9.1% | 171 | 0.0% | 0.02% | +7.1% |
| Q3 2014 | $22,000 | +10.0% | 171 | +5.6% | 0.01% | +16.7% |
| Q2 2014 | $20,000 | -9.1% | 162 | -4.7% | 0.01% | -14.3% |
| Q1 2014 | $22,000 | – | 170 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |